Pipeline
We focus our research on diseases that have typically been overlooked and underserved
Whether we start from drug discovery or pick up an opportunity mid-pipeline, our team’s seamless coordination across functions and unwavering focus on transforming patients’ lives enable us to advance product candidates at any stage.
For more information on our approved products, visit our Therapies page.
Product pipeline
Mycobacterium avium complex (MAC) Lung Disease
| Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Commercial |
ARIKAYCE® (Amikacin Liposome Inhalation Suspension)*
Refractory MAC Lung Disease
Commercial
Nontuberculous mycobacterial (NTM) lung disease is a rare and serious disorder most commonly caused by a group of bacteria called Mycobacterium avium complex (MAC).1 People who have bronchiectasis, COPD, and asthma are at greater risk of getting NTM lung disease.2,3,4
Amikacin Liposome Inhalation Suspension
MAC Lung Disease
Phase 3
Nontuberculous mycobacterial (NTM) lung disease is a rare and serious disorder most commonly caused by a group of bacteria called Mycobacterium avium complex (MAC).1 People who have bronchiectasis, COPD, and asthma are at greater risk of getting NTM lung disease.2,3,4
Neutrophil-Driven Inflammatory Conditions
| Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Commercial |
BRINSUPRI® (Brensocatib)**
Non-Cystic Fibrosis Bronchiectasis
Commercial
Non-cystic fibrosis bronchiectasis (NCFBE) is a chronic pulmonary disorder in which the bronchi become permanently dilated due to a vicious cycle of inflammation and complications from prior infections.5,6 The condition is marked by frequent pulmonary exacerbations requiring antibiotic therapy and/or hospitalizations.
Brensocatib: DPP1 Inhibitor
Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)
Phase 2
CRS without nasal polyps is a chronic inflammatory process of the mucus membranes inside the sinuses. The most common symptoms include a decreased sense of smell and facial pain.7
Brensocatib: DPP1 Inhibitor
Hidradenitis Suppurativa (HS)
Phase 2
HS is a chronic relapsing inflammatory disorder, characterized by painful, inflamed, and swollen lesions affecting hair follicles, often in the armpits, groin, and skin folds.8
Additional Rare Pulmonary Diseases
| Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Commercial |
Treprostinil Palmitil Inhalation Powder (TPIP)
Pulmonary Hypertension associated with Interstitial Lung Diseases (PH-ILD)
Phase 3
Interstitial lung diseases (ILD) comprise a large group of diseases that cause fibrosis (scarring) of the lungs. Pulmonary hypertension (high blood pressure in the lungs) is a common and important complication of several ILDs that is associated with reduced exercise capacity and poor prognosis.9,10 PH-ILD is also known as WHO Group 3 Pulmonary Hypertension.
Treprostinil Palmitil Inhalation Powder (TPIP)
Pulmonary Arterial Hypertension (PAH)
Phase 2
Pulmonary arterial hypertension (PAH) is a serious, progressive, rare disease involving narrowing and constriction of the pulmonary arteries that carry blood from the right side of the heart to the lungs.11 PAH is also known as WHO Group 1 Pulmonary Hypertension.
Genetic Diseases
| Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Commercial |
INS1201: Gene Therapy
Duchenne Muscular Dystrophy (DMD)
Phase 1
DMD is caused by a genetic mutation that prevents the body from producing dystrophin, a protein that muscles need to work properly. Without it, muscle cells become damaged and weaken.12 DMD is the most common childhood onset form of muscular dystrophy and affects males almost exclusively.13
INS1202: Gene Therapy
Amyotrophic Lateral Sclerosis (ALS)
Pre-clinical
ALS is a progressive neurological disease that affects the nerve cells in the brain and spinal cord that control voluntary muscle movement and breathing. As these nerve cells degenerate, the body’s muscles begin to weaken and waste away. Eventually, the brain loses its ability to control voluntary movements like walking, talking, chewing, and breathing. Most people with ALS die of respiratory failure within three to five years from initial symptom onset.14
Pre-Clinical Research
| Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Commercial |
INS1203: Gene Therapy
Stargardt Disease
Pre-clinical
Stargardt disease is a rare genetic eye disease caused by the buildup of fatty material on the macula, the small part of the retina needed for sharp, central vision.15 The disease leads to the loss of central vision in both eyes, typically beginning in childhood. Today, there are no treatments available for the disease, and management options focus on optimizing patients’ remaining sight.
INS1033: Next-Generation DPP1 Inhibitor
Inflammatory Bowel Disease
Pre-clinical
Inflammatory bowel disease (IBD) refers to a group of chronic inflammatory diseases, including ulcerative colitis and Crohn’s disease, that cause swelling of the tissues in the digestive tract.16 It occurs when the body’s natural defense system mistakenly attacks healthy bowel cells.17 Symptoms typically flare up and then recede and often include diarrhea, stomach pain, rectal bleeding, fatigue, and weight loss. While IBD can be mild for some, for others, it can cause disability and lead to life-threatening complications.16
INS1033: Next-Generation DPP1 Inhibitor
Rheumatoid Arthritis
Pre-clinical
Rheumatoid arthritis is a chronic, inflammatory condition in which the body’s immune system attacks its own tissues, causing significant inflammation in joints and other organs. It most commonly affects small joints in the wrists, hands, and feet, causing joint pain, stiffness, swelling, and decreased flexibility, but can also affect larger joints and organs such as the skin, eyes, heart, lungs, and blood vessels. Despite medical advancements, rheumatoid arthritis can still cause long-term damage and increase the risk of heart disease.18,19
Next-Generation DPP1 Inhibitors
Multiple indications
Pre-clinical
Other Pre-Clinical Research
Multiple indications
Pre-clinical
The safety and efficacy of investigational products and/or investigational uses of commercial products have not been approved by any health authority.
* In the U.S., as a condition of accelerated approval, Insmed is conducting an additional clinical study to support full approval. Full approval has been granted in Europe and Japan.
** Brensocatib remains under review for non-cystic fibrosis bronchiectasis by regulatory authorities in the UK and Japan.
References
- Adjemian J, Prevots DR, Gallagher J, Heap K, Gupta R, Griffith D. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Ann Am Thorac Soc. 2014;11(1):9-16.
- Mirsaeidi M, Hadid W, Ericsoussi B, Rodgers D, Sadikot RT. Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis. Int J Infect Dis.2013;17(11):e1000-e1004.
- Andréjak C, Nielsen R, Thomsen VØ, Duhaut P, Sørensen HT, Thomsen RW. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013;68(3):256-262.
- Fritscher LG, Marras TK, Bradi AC, Fritscher CC, Balter MS, Chapman KR. Nontuberculous mycobacterial infection as a cause of difficult-to-control asthma: a case-control study. Chest. 2011;139(1):23-27.
- Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013 (Weycker). https://www.ncbi.nlm.nih.gov/pubmed/28555504. Accessed December 2020.
- Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity (Flume). https://www.ncbi.nlm.nih.gov/pubmed/30215383. Accessed December 2020.
- Cho SH, Kim DW, Gevaert P. Chronic Rhinosinusitis without Nasal Polyps. J Allergy Clin Immunol Pract. 2016 ; 4(4): 575–582.
- Phan K, Charlton O, Smith SD. Global Prevalence of Hidradenitis Suppurative and Geographical Variation—Systematic Review and Meta-Analysis. Phan et al. Biomedical Dermatology (2020) 4:2.
- American Lung Association. Interstitial Lung Disease. https://www.lung.org/lung-health-diseases/lung-disease-lookup/interstitial-lung-disease. Accessed January 2021.
- Caminati A. Pulmonary hypertension in chronic interstitial lung diseases. European Respiratory Review 2013 22: 292-301 https://err.ersjournals.com/content/22/129/292. Accessed January 2021.
- Pulmonary Hypertension Association. About Pulmonary Hypertension. https://phassociation.org/types-pulmonary-hypertension-groups/. Accessed January 2021.
- Muscular Dystrophy Association. Duchenne Muscular Dystrophy (DMD). https://www.mda.org/disease/duchenne-muscular-dystrophy. Accessed April 2023.
- National Institute of Child Health and Human Development. What are the types and symptoms of muscular dystrophy (MD)? https://www.nichd.nih.gov/health/topics/musculardys/conditioninfo/types. Accessed April 2023.
- National Institute of Neurological Disorders and Stroke. Amyotrophic Lateral Sclerosis (ALS). https://www.ninds.nih.gov/health-information/disorders/amyotrophic-lateral-sclerosis-als. Accessed February 2024.
- National Eye Institute. Stargardt Disease. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/stargardt-disease. Accessed March 2023.
- Mayo Clinic. Inflammatory bowel disease (IBD). https://www.mayoclinic.org/diseases-conditions/inflammatory-bowel-disease/symptoms-causes/syc-20353315. Accessed October 2025.
- U.S. Centers for Disease Control and Prevention. Inflammatory Bowel Disease (IBD) Basics. https://www.cdc.gov/inflammatory-bowel-disease/about/index.html. Accessed October 2025.
- Mayo Clinic. Rheumatoid arthritis. https://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/symptoms-causes/syc-20353648. Accessed October 2025.
- American College of Rheumatology. Rheumatoid Arthritis. https://rheumatology.org/patients/rheumatoid-arthritis. Accessed October 2025.
Clinical Trials
To make a real-world impact, it’s vital that we understand real-life challenges. Our clinical trials are designed in collaboration with patients to ensure their insights and needs are considered.
Your Privacy Choices